{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:15:37Z","timestamp":1790964937505,"version":"4.1.0"},"reference-count":88,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling pathway. However, NF2 has functions beyond regulation of the Hippo pathway, raising the possibility that NF2 contributes to MPM via Hippo-independent mechanisms. (2) We performed weighted gene co-expression analysis (WGCNA) in transcriptomic and proteomic datasets obtained from The Cancer Gene Atlas (TCGA) MPM cohort to identify clusters of co-expressed genes highly correlated with NF2 and phospho (p)-YAP protein, surrogate markers of active Hippo signaling and YAP inactivation. The potential targets are experimentally validated using a cell viability assay. (3) MPM tumors with NF2 loss-of-function are not associated with changes in p-YAP level nor YAP\/TAZ activity score, but are characterized by a deficient B-cell receptor (BCR) signaling pathway. Conversely, MPM tumors with YAP activation display exhausted CD8 T-cell-mediated immunity together with significantly upregulated PD-L1, which is validated in an independent MPM cohort, suggesting a potential benefit of immune-checkpoint inhibitors (ICI) in this patient subset. In support of this, mutations in core Hippo signaling components including LATS2, but not NF2, are independently associated with better overall survival in response to ICI in patients. Additionally, based on cancer cell line models, we show that MPM cells with a high Hippo-YAP activity are particularly sensitive to inhibitors of BCR-ABL\/SRC, stratifying a unique MPM patient subset that may benefit from BCR-ABL\/SRC therapies. Furthermore, we observe that NF2 physically interacts with a considerable number of proteins that are not involved in the canonical Hippo-YAP pathway, providing a possible explanation for its Hippo-independent role in MPM. Finally, survival analyses show that YAP\/TAZ scores together with p-YAP protein level, but not NF2, predict the prognosis of MPM patients. (4) NF2 loss-of-function and dysregulated Hippo-YAP pathway define distinct MPM subsets that differ in their molecular features and prognosis, which has important clinical implications for precision oncology in MPM patients.<\/jats:p>","DOI":"10.3390\/cancers13071561","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T16:01:57Z","timestamp":1617033717000},"page":"1561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-5910","authenticated-orcid":false,"given":"Haitang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-7329","authenticated-orcid":false,"given":"Sean R. R.","family":"Hall","sequence":"additional","affiliation":[{"name":"Gillies McIndoe Research Institute, 6242 Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute for Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-079X","authenticated-orcid":false,"given":"Ralph A.","family":"Schmid","sequence":"additional","affiliation":[{"name":"Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0695-453X","authenticated-orcid":false,"given":"Swee T.","family":"Tan","sequence":"additional","affiliation":[{"name":"Gillies McIndoe Research Institute, 6242 Wellington, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-6520","authenticated-orcid":false,"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of General Thoracic Surgery, Department of BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, 3008 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1758835920971421","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"579464","DOI":"10.3389\/fonc.2020.579464","article-title":"Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight","volume":"10","author":"Xu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma","volume":"75","author":"Guo","year":"2014","journal-title":"Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"Totaro","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129397","DOI":"10.1016\/j.bbagen.2019.07.006","article-title":"The posttranslational modifications of Hippo-YAP pathway in cancer","volume":"1864","author":"Yan","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yang, H., Xu, D., Yang, Z., Yao, F., Zhao, H., Schmid, R.A., and Peng, R.-W. (2020). Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12.","DOI":"10.3390\/cancers12082310"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: An R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinform."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sato, T., and Sekido, Y. (2018). NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19040988"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lee, S., Karas, P.J., Hadley, C.C., Bayley, V.J.C., Khan, A.B., Jalali, A., Sweeney, A.D., Klisch, T.J., and Patel, A.J. (2019). The Role of Merlin\/NF2 Loss in Meningioma Biology. Cancers, 11.","DOI":"10.3390\/cancers11111633"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","article-title":"Functional inactivation of NF2\/merlin in human mesothelioma","volume":"64","author":"Thurneysen","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1440-1827.2011.02666.x","article-title":"Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation","volume":"61","author":"Sekido","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13008-016-0013-6","article-title":"New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics","volume":"11","author":"He","year":"2016","journal-title":"Cell Div."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00005-006-0017-z","article-title":"ETS transcription factors and regulation of immunity","volume":"54","author":"Gallant","year":"2006","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.onc.1210637","article-title":"POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17","volume":"27","author":"Zhao","year":"2007","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: An \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation","volume":"135","author":"Tedder","year":"1985","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"ref_26","first-page":"1","article-title":"Neurofibromatosis type 2 protein, NF2: An uncoventional cell cycle regulator","volume":"33","author":"Beltrami","year":"2013","journal-title":"Anticancer. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/MCB.01139-07","article-title":"Localization to the Cortical Cytoskeleton Is Necessary for Nf2\/Merlin-Dependent Epidermal Growth Factor Receptor Silencing","volume":"28","author":"Cole","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/onc.2008.427","article-title":"Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas","volume":"28","author":"Lallemand","year":"2008","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hsu, P.-C., Jablons, D.M., Yang, C.-T., and You, L. (2019). Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153821"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eaaz4589","DOI":"10.1126\/scitranslmed.aaz4589","article-title":"A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components","volume":"12","author":"Nilsson","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/1541-7786.MCR-15-0305","article-title":"Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway","volume":"14","author":"Ehmer","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/13543776.2018.1549226","article-title":"Hippo pathway inhibition by blocking the YAP\/TAZ\u2013TEAD interface: A patent review","volume":"28","author":"Crawford","year":"2018","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-018-1079-6","article-title":"Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia","volume":"35","author":"Marsola","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_35","first-page":"1","article-title":"Activation of Aurora A kinase increases YAP stability via blockage of autophagy","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Guillerey","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 enhances tumor response to anti\u2013PD-1 immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.2174\/092986711798184271","article-title":"Effects of BCR-ABL inhibitors on anti-tumor immunity","volume":"18","author":"Krusch","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_41","first-page":"979","article-title":"Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma","volume":"134","author":"Ke","year":"1989","journal-title":"Am. J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0027-5107(92)90011-P","article-title":"SV40 T antigen induced chromosomal changes reflect a process that is both clastogenic and aneuploidogenic and is ongoing throughout neoplastic progression of human fibroblasts","volume":"284","author":"Ray","year":"1992","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/ncb2634","article-title":"Hippo\u2013YAP and mTOR pathways collaborate to regulate organ size","volume":"14","author":"Csibi","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Klebanoff, C.A., Crompton, J.G., Leonardi, A.J., Yamamoto, T.N., Chandran, S.S., Eil, R.L., Sukumar, M., Vodnala, S.K., Madhusudhanan, S., and Ji, Y. (2017). Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2.","DOI":"10.1172\/jci.insight.95103"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/icb.2010.88","article-title":"CD40-activated B cells contribute to mesothelioma tumor regression","volume":"89","author":"Jackaman","year":"2010","journal-title":"Immunol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.gendis.2019.06.006","article-title":"Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies","volume":"6","author":"Shen","year":"2019","journal-title":"Genes Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Yarchoan, M., Albacker, L.A., Hopkins, A.C., Montesion, M., Murugesan, K., Vithayathil, T.T., Zaidi, N., Azad, N.S., Laheru, D.A., and Frampton, G.M. (2019). PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight, 4.","DOI":"10.1172\/jci.insight.126908"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1242\/dev.096537","article-title":"Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap\/Taz transcriptional coactivators","volume":"140","author":"Lavado","year":"2013","journal-title":"Development"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCRESAHA.116.308586","article-title":"NF2 Activates Hippo Signaling and Promotes Ischemia\/Reperfusion Injury in the Heart","volume":"119","author":"Matsuda","year":"2016","journal-title":"Circ. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.1038\/ncomms12309","article-title":"A critical role for NF2 and the Hippo pathway in branching morphogenesis","volume":"7","author":"Reginensi","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1101\/gad.333435.119","article-title":"Critical roles of phosphoinositides and NF2 in Hippo pathway regulation","volume":"34","author":"Hong","year":"2020","journal-title":"Genes Dev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the Roots of Cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2013.130","article-title":"Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma","volume":"108","author":"Mezzapelle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/jcmm.13182","article-title":"Targeting YAP in malignant pleural mesothelioma","volume":"21","author":"Zhang","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","article-title":"The Hippo Pathway Kinases LATS1\/2 Suppress Cancer Immunity","volume":"167","author":"Moroishi","year":"2016","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Taha, Z., Van Rensburg, H.J.J., and Yang, X. (2018). The Hippo Pathway: Immunity and Cancer. Cancers, 10.","DOI":"10.3390\/cancers10040094"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41423-018-0007-1","article-title":"Role of Hippo signaling in regulating immunity","volume":"15","author":"Hong","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18632\/oncoscience.398","article-title":"The Hippo pathway and cancer immunity: Friend or foe?","volume":"5","author":"Yang","year":"2018","journal-title":"Oncoscience"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma","volume":"23","author":"Tranchant","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","article-title":"YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/2159-8290.CD-17-1320","article-title":"Tissue-Specific Immunoregulation: A Call for Better Understanding of the \u201cImmunostat\u201d in the Context of Cancer","volume":"8","author":"Pao","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Yang, H., Hall, S.R.R., Sun, B., and Yao, F. (2020). Comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d. Br. J. Cancer, 1\u20132.","DOI":"10.1038\/s41416-020-01214-8"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Yang, H., Yao, F., Davis, P.F., Tan, S.T., and Hall, S.R.R. (2021). CD73, Tumor Plasticity and Immune Evasion in Solid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13020177"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1","volume":"78","author":"Azad","year":"2018","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clim.2017.10.002","article-title":"Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens","volume":"187","author":"DeFalco","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1158\/1078-0432.CCR-20-1767","article-title":"Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment","volume":"26","author":"Chen","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS  J. Integr. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Xu, D., Yang, H., Berezowska, S., Gao, Y., Liang, S.-Q., Marti, T.M., Hall, S.R.R., Dorn, P., Kocher, G.J., and Schmid, R.A. (2019). Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers, 11.","DOI":"10.3390\/cancers11101502"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-019-0158-7","article-title":"HSP90\/AXL\/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer","volume":"8","author":"Yang","year":"2019","journal-title":"Oncogenesis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nmeth.2650","article-title":"TCPA: A resource for cancer functional proteomics data","volume":"10","author":"Li","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: Protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Yang, H., Zhao, L., Gao, Y., Yao, F., Marti, T.M., Schmid, R.A., and Peng, R.-W. (2020). Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12113273"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/7\/1561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:53:18Z","timestamp":1760363598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/7\/1561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":88,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13071561"],"URL":"https:\/\/doi.org\/10.3390\/cancers13071561","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]}}}